Guerbet, a global leader in medical imaging, announces the registration of Vectorio, kit for imaging of hepatocellular carcinoma (HCC), in Canada.
Vectorio is a set of Lipiodol resistant medical devices (1) including patented syringes, stopcock and sampling devices.
Vectorio is dedicated to Lipiodol Ultra Fluid Injection for imaging of liver tumors in adults with known hepatocellular carcinoma during interventional oncology procedures.
HCC is the most common primary liver cancer and is the fourth biggest cause of death due to cancer worldwide (2).
This medical device:
Designed and manufactured in France, Vectorio started its commercial launch in September 2017 in European countries. Today, Vectorio for imaging of HCC is registered in Canada & Germany. Vectorio is also registered in 25 countries where cTACE procedures are approved for Lipiodol Ultra Fluid (3,4).
Guerbet's Vectorio for Interventional Oncology Is Approved in Canada. Appl Radiol.